Lynx, Wilex Will Study Gene Expression Changes With New Cancer Drug

Apr 23, 2002

NEW YORK, April 23-Lynx Therapeutics and Wilex AG will work together to identify genes regulated by Wilex' lead compound for renal cell carcinoma, the companies said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

OncoDNA, Everything Genetic Sign Distribution Deal
Luminex Receives FDA Clearance for C. Diff Assay
Top Five Articles on GenomeWeb Last Week: Dogs, Courtagen, Thermo Fisher, and More
Genetic Technologies Facing Nasdaq Delisting
Exosome Diagnostics Completes $30 Million Series C Financing
Researchers Find MRSA Genesis Occurred Years Before Clinical Introduction of Methicillin

The Scan

Helix Launches 'App Store'

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

More CAR-T Therapies Sought

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Telomeres of Spawning Salmon

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

This Week in PLOS

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.

Main menu